Modality
Bispecific Ab
MOA
TNFi
Target
GLP-1R
Pathway
Sphingolipid
Obesity
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
Sep 2019
→ Jul 2025
Phase 1Current
NCT08649931
807 pts·Obesity
2019-09→2025-07·Completed
807 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-278mo agoPh2 Data· Obesity
2026-12-148mo awayOrphan Drug· Obesity
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1/2
Complet…
Catalysts
Ph2 Data
2025-07-27 · 8mo ago
Obesity
Orphan Drug
2026-12-14 · 8mo away
Obesity
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08649931 | Phase 1/2 | Obesity | Completed | 807 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R |